{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:19:50Z","timestamp":1782587990476,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.atherosclerosis.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T04:42:24Z","timestamp":1665636144000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization"],"prefix":"10.1016","volume":"363","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-9063","authenticated-orcid":false,"given":"Bernhard","family":"Zierfuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"H\u00f6baus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Feldscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Hannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Koppensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Stangl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1161\/01.CIR.100.11.1154","article-title":"Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study","volume":"100","author":"Kronenberg","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1078-5884(97)80220-1","article-title":"Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease","volume":"14","author":"Cheng","year":"1997","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.27.2.517","article-title":"Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan","volume":"27","author":"Tseng","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib15","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehl441","article-title":"Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study","volume":"28","author":"Tzoulaki","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib17","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease","volume":"285","author":"Ridker","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.107.719369","article-title":"Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk","volume":"117","author":"Pradhan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/1526602817728068","article-title":"Usefulness of lipoprotein(a) for predicting clinical outcomes after endovascular therapy for aortoiliac atherosclerotic lesions","volume":"24","author":"Hishikari","year":"2017","journal-title":"J. Endovasc. Ther."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015355","article-title":"Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease","volume":"9","author":"Golledge","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib21","series-title":"High Lipoprotein(a) Is Associated with Major Adverse Limb Events after Femoral Artery Endarterectomy","author":"Verwer","year":"2021"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2022.10.002_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from eas and eflm","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib24","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/2047487313483600","article-title":"Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib28","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2018.11.040","article-title":"Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia","volume":"281","author":"Vuorio","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein (a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1373\/clinchem.2003.030031","article-title":"Apolipoprotein (a) size and lipoprotein (a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study","volume":"50","author":"Rifai","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2011.163","article-title":"Index event bias as an explanation for the paradoxes of recurrence risk research","volume":"305","author":"Dahabreh","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib36","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0735-1097(95)00299-5","volume":"26","author":"Barbash","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ije\/25.2.282","article-title":"The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease","volume":"25","author":"Stoffers","year":"1996","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/028134398750003142","article-title":"Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive Disease","volume":"16","author":"Hooi","year":"1998","journal-title":"Scand. J. Prim. Health Care"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0021-9150(03)00204-1","article-title":"High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study","volume":"172","author":"Diehm","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejvs.2010.02.009","article-title":"Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry","volume":"39","author":"Cambou","year":"2010","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib42","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/01.CIR.82.6.1925","article-title":"Intermittent claudication, heart disease risk factors, and mortality","volume":"82","author":"Smith","year":"1990","journal-title":"The Whitehall Study, Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.10.002_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/ije\/20.2.384","article-title":"Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population","volume":"20","author":"Fowkes","year":"1991","journal-title":"Int. J. Epidemiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022014691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022014691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:52:05Z","timestamp":1758156725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022014691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":43,"alternative-id":["S0021915022014691"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.10.002","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}